Mikart and Nano PharmaSolutions Announce Positive Interim Data from NT-301 Phase 1 Trial and Expansion of NanoTransformer® Manufacturing Capabilities
NT-301, a drug-device combination product manufactured at Mikart's GMP facility in Atlanta, is powered by NanoTransformer® technology, Nano PharmaSolutions' patented nanodrug manufacturing platform [...]
Dr. Kay Olmstead (CEO) presents the interim Phase 1 clinical trial results at IPAC-RS Conference
Dr. Kay Olmstead was an invited guest speaker at the annual International Pharmaceutical Aerosol Consortium on Regulation & Science (IPAC-RS) conference held in [...]
NPS presents patient-centric delivery system, Nano-CNS™ during DCAT conference in Lugano, Italy
Dr. Kay Olmstead (CEO) presented Nano PharmaSolutions Nano-CNS™ platform technology for delivering neurotherapeutics via powder nasal spray device during the DCAT Summit, held [...]
( Case Study ) WTCSD, EDC support Nano PharmaSolutions in securing $17K in grants, FTE, and global connectivity
August 2024 Nano PharmaSolutions (NPS) is a woman-owned innovative drug solutions provider that turns insoluble drug molecules into nanoparticles to increase their bioavailability to [...]
Mikart and Nano PharmaSolutions Complete Key Milestones
NPS is now prepared to install our NanoTransformer™ at Mikart's Atlanta facility, as a key part of our groundbreaking collaboration. Read the full [...]
NPS’ NanoTransformer™ Technology Featured in Drug Development & Delivery
In drug-dev.com's special feature report, Solubility & Bioavailability: Difficult Beasts to Tame, NPS explains how chemical & additive free nanoformulation tackles solubility and [...]
